Sage Ends Dalzanemdor Trials After Multiple Phase II Failures in Huntington's, Parkinson's, and Alzheimer's

Sage Therapeutics has officially terminated the development of dalzanemdor after a troubling series of Phase II trial failures across major neurological conditions, including Huntington's, Parkinson’s, and Alzheimer's diseases. The decision to halt further development was primarily driven by the drug's inability to demonstrate effectiveness in improving cognitive function among patients with cognitive impairments due to Huntington’s disease, as evidenced by its performance in a trial involving 189 participants that failed to outperform a placebo[1][2]. The succession of negative outcomes not only impacted the company’s pipeline but also resulted in substantial layoffs, including more than half of its R&D team[2]. As Sage pivots towards other potential treatments, this move to terminate dalzanemdor reflects a strategic realignment in response to its recent setbacks[1].